BCL-X <sub>L</sub> –targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors
Andrew S. Judd(AbbVie (United States)), Andrew J. Souers(AbbVie (United States))
Cited by 18
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
|Science Translational Medicine|2015|541
Discovery of a Potent and Selective BCL-X <sub>L</sub> Inhibitor with <i>in Vivo</i> Activity
|ACS Medicinal Chemistry Letters|2014|331
Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity
|Journal of Medicinal Chemistry|2015|152